US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

(Stockholm, May 5, 2023) On May 19, 2023 Asarina Pharma’s positive results from its Phase IIa Study in Tourette Syndrome will be presented at TicCon, the Virtual National Conference of the Tourette Association of America, by Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah). The results were an important target validation of Assoc Prof. Bortolato’s thesis that the powerful neurosteroid Allopregnanolone (ALLO) is a key target in the pathogenesis of Tourette, and that Asarina’s endogenous compound Sepranolone modulates ALLO´s effects.The Phase IIa results

Asarina Pharma AB (publ) releases Annual Report 2022

(Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements and outlook. Additional content includes investor FAQs with CEO Peter Nordkild and clinical insights from Clinical Neurologist Dr Heidi Biernat (Head of the Tourette Clinic at Bispebjerg University Hospital) on today’s Tourette treatment landscape and patients’ experience of Sepranolone.The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 22 May 2023 at 10:00 CEST at Fredersen Advokatbyrå's premises at Birger Jarlsgatan 8, Stockholm. Registration starts at 09:30 CEST.NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate Shareholders that wish to participate in the AGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 11 May

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

(Stockholm, April 1, 2023) Asarina Pharma today releases results from its Phase IIa study of the endogenous neurosteroid Sepranolone for the treatment of Tourette Syndrome. The primary objective of the study was to investigate the efficacy of Sepranolone, compared to Standard of Care, to reduce tic severity in patients with Tourette Syndrome at twelve weeks, using the change from baseline in Yale Global Tic Severity Scale (YGTSS) total score. The study found that Sepranolone reduced the YGTSS score by 8.6 points or 28.0%. This was compared to a 3.9 point or 12.6% reduction in the control

Asarina Pharma AB (publ) releases Year-End Report 2022

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate remained unexpectedly low throughout the study. Results continue to be expected at the end of March 2023.FINANCIAL HIGHLIGHTS · Operating costs (MSEK 6.7) well under control  · Cash reserves at year-end (MSEK 13.6) enough to finance completion

Last Patient Last Visit for landmark Tourette Syndrome study

(Stockholm, 2 February 2023.) The Last Patient’s Last Visit took place on 1 February less than 12 months after the study’s initiation in Asarina Pharma’s Phase IIa clinical study in Sepranolone for the treatment of Tourette Syndrome. All patient examination and treatment in the study has now been completed and the patient dropout rate has remained unexpectedly low. Topline results are expected on schedule at the end of March 2023.A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active group’ of 17 who received

Patient recruitment completed in landmark Tourette syndrome study

(Stockholm, 14 October 2022.) Asarina Pharma has completed the recruitment of patients to its Phase IIa clinical study in Tourette syndrome with a total of 28 patients enrolled and the last patient randomized on October 14. The dropout rate in the study remains unexpectedly low. Topline results are expected at the end of Q1 2023. The study compound, Sepranolone, is an endogenous neurosteroid, an entirely new treatment modality for Tourette. It has demonstrated a strong safety prolife in multiple previous clinical studies, and reduced tics without inducing any motor side effects in previous

Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD

(Stockholm, 6 October 2022.) A new study in the journal Neurobiology of Stress reconfirms the central role the neurosteroid Allopregnanolone (ALLO) plays in stress-related conditions such as Tourette syndrome and OCD, and the efficacy of its endogenous modulator isoallopregnanolone in modulating its negative effects. This is the most extensive of four preclinical studies confirming these findings, significantly increasing the Translatability of data. Asarina Pharma is testing isoallopregnanolone (under the name Sepranolone) for Tourette syndrome in a Phase IIa study, with the last patient

Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought

A new study by the U.S. CDC (Centers for Disease Control and Prevention) estimates that 1-in-50 children in the US may be affected by Tourette or persistent tic disorders, previous estimates were 1-in-100, and that up to 450,000 U.S. children and adults have Tourette. Asarina Pharma is currently carrying out a phase IIa clinical study into Sepranolone, an endogenous neurohormonal treatment for Tourette that aims to reduce tics with no significant side effects.A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been

Asarina Pharma AB (publ) Q2 2022 Report released

CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second quarter of 2022. With more than two thirds of patients recruited and a drop-out rate of under 5%, the study remains fully funded, and we remain confident of reporting topline results by the end of Q1 2023.”FINANCIAL HIGHLIGHTS · Total operating costs have been further reduced to SEK 4.0 million (Q2/2021: SEK 16.0 million.) This reflects that all resources are now being allocated to our phase IIa study in Tourette · Present funding still

Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen

Solna, 23 June 2022. The Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) has resolved on a directed issue of 3,896,885 shares to Östersjöstiftelsen (ÖSS) following a request for conversion in accordance with convertible loan agreement between Asarina Pharma and ÖSS entered into in May 2021.On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”). ÖSS has now, in accordance with the Loan Agreement, requested that Asarina Pharma repay the outstanding loan amount plus

Asarina Pharma AB (publ) Q1 2022 Report released

Peter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals of our phase IIa Tourette study, despite tail-end Covid-19 effects at our study sites. We firmly expect to continue to do so. The study remains fully funded. We remain confident of reporting topline results in Q1 2023.”FINANCIAL HIGHLIGHTS · Staff costs declined to 0.6 (1.9) MSEK due to the previously communicated reduction in working time for the Asarina team in Q3/2021 · External R&D costs amounted to 2.6 (4.0) MSEK, the majority related to

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 4 May 20022.  The Annual General Meeting was carried out through advance voting (postal voting) only.Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021 as well as the balance sheet and consolidated balance sheet as of 31 December 2021. The members of the Board of Directors and the Managing Director were discharged from liability for the financial year 2021.

ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED

Peter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on Sepranolone’s potential and move forward with focus and optimism.”FINANCIAL HIGHLIGHTS · Total operating costs were reduced by more than 50% to SEK 38.3 million. · R&D costs dropped to SEK 29.9 millionfrom SEK 63.7 million in 2020.The Company received a

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.  The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 4 May 2022.Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the Meeting will be held without physical

Asarina Pharma AB (publ) Year-end Report 2021 released

Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in our search to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.”FINANCIAL HIGHLIGHTS · Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20) · Cash balance at 31 December 2021

First patient in for landmark Tourette Syndrome study

(Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen. The Asarina compound being trialled, Sepranolone, is an endogenous neurosteroid that has already demonstrated a strong safety profile in previous clinical studies. In preclinical studies it was found to reduce tics effectively without inducing any motor side effects. Today’s pharmaceutical treatments for Tourette, such as the anti-psychotic Haldol, involve multiple severe side effects.

Asarina Pharma receives final approval for landmark phase IIa Tourette study

(Stockholm, Sweden, 22 December, 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlogThe phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette department, and Bispebjerg University hospital. 30 patients ranging from 12 to 45 years old will be included in the study. There is an acute un-met need for a safe and effective pharmaceutical

Asarina Pharma AB (publ) Q3 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.”FINANCIAL HIGHLIGHTS · Significant reduction in operating costs in Q3 · Cash position on 30 September 2021 (SEK 23.5 million) still expected to cover the Tourette study R&D HIGHLIGHTS · TOURETTE SYNDROME Following an administrative delay from Region Hovedstaden (the Capital Region of Denmark) we expect to receive final legal

PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology

(Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when examined in an extended 9-day analysis of symptom reduction. Senior PMDD Key Opinion Leaders who co-authored the publication include Dr Nick Panay (Imperial College London), Prof. Shaughn O’Brien (Royal Stoke University Hospital, UK), Prof. C. Neill Epperson (Dept. Psychiatry, University of Colorado), Prof

Administrative backlog at public authority causes short-term delay in Tourette study

(Stockholm, 16 September, 2021.) An administrative backlog due to Covid-19 at The Capital Region of Denmark (Region Hovedstaden) is causing a delay of approx. 3 months to the initiation of Asarina Pharma’s phase IIa study in Tourette Syndrome. The study is now expected to start in December 2021 and be completed at the end of 2022.Asarina Pharma’s Clinical Trial Application for its phase IIa study in Tourette Syndrome was approved by the Danish Medical Agency in May 2021 and has now received approval from the Ethics Committee. The only outstanding matter is the contract with the two clinical

Asarina Pharma AB (publ) Q2 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US patent for Sepranolone for the treatment of Tourette, OCD and pathological gambling. Together, these developments signal the end of an important chapter in our history, and the beginning of a new journey.”FINANCIAL HIGHLIGHTS · Operating costs (SEK 16.0 million)

Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While a 25% reduction in menstrual migraine days was achieved across the patient population, a statistically significant difference compared to placebo was not obtained for the study’s primary and secondary endpoints. The study confirms a positive safety and tolerability profile for Sepranolone. Asarina Pharma will continue its fully financed development program for Sepranolone in Tourette syndrome.CEO Peter Nordkild: “Obviously we had

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe